ReachRxResearch
Home
Research
Sign Up
Phosphorylated MLKL is increased in urinary extracellular vesicles of women with preeclampsia
Back to Research Hub
  1. Home
  2. Research Hub
  3. Phosphorylated MLKL is increased in urin…

Phosphorylated MLKL is increased in urinary extracellular vesicles of women with preeclampsia

Pregnancy Hypertension·August 22
Obstetrics & GynecologyLimited evidencePreeclampsiaCase-Control StudyBiomarkerAdultMLKLPhosphorylated MLKL

Summary

View source

What was studied

This study evaluated whether necroptosis-associated proteins — total MLKL and phosphorylated MLKL (pMLKL) — are elevated in urinary extracellular vesicles (uEVs) from 22 women with preeclampsia (PE) vs. 22 gestation-matched normotensive pregnant controls, with a secondary cohort of 4 heavily proteinuric PE cases.

Key findings

pMLKL was detected in uEVs significantly more often in PE than controls (6/22 vs. 0/22, P = 0.021); total MLKL showed a non-significant trend (10/22 vs. 5/22, P = 0.203). In the heavily proteinuric PE subcohort, pMLKL was found in 3/4 samples. PALP (placental marker) appeared in 2/12 PE and 1/12 NP uEV samples, suggesting occasional placental origin.

Study limitations

- Very small sample sizes (n=22 per group; n=4 in the proteinuric subcohort) limit statistical power and generalizability. - Cross-sectional design cannot establish whether uEV pMLKL is a cause, consequence, or biomarker of PE progression. - PALP and NKCC2 origin markers were only assessed in a subset (12/22 per group), leaving uEV tissue source largely unresolved.

Clinical implications

uEV pMLKL is a promising, non-invasive urinary biomarker candidate for preeclampsia, but findings are preliminary given the small cohort. Clinicians should await validation in larger studies before considering this in practice.

Caveats

  • PALP and NKCC2 organ-origin markers were tested in only a subset of participants (12 per group), limiting conclusions about uEV tissue source.
  • The study design is observational and cross-sectional; 'case-control' is an approximation — the paper uses gestation-matched controls but does not explicitly label itself as a case-control study.
  • Total cohort size is 48 (22 PE + 22 NP in Cohort A; 4 PE + 4 NP implied in Cohort B), but Cohort B controls are not explicitly enumerated in the abstract — sample_size tag reflects the primary cohort plus Cohort B as described.

Related Questions

Explore related topics

What biomarkers in urine or urinary extracellular vesicles are useful for diagnosing preeclampsia?What is the role of necroptosis in preeclampsia pathophysiology?How reliable is urinary extracellular vesicle isolation by ultracentrifugation for biomarker studies in pregnancy?

Publication Details

Year
2026
Journal
Pregnancy Hypertension
Sample Size
n=48
Source
View article
Keep scrolling
More content below.
Up Next